Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome

Trial Profile

Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions
  • Acronyms T-Force GOLD Plus
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 15 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top